NA
GMAB icon

Navellier & Associates’s Genmab GMAB Stock Holding History

Navellier & Associates’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,600
Closed -$903K – 339
2023
Q3 		$903K Buy
25,600
+1,485
+6% +$56.6K 0.15% 144
2023
Q2 		$917K Buy
24,115
+1,491
+7% +$59.4K 0.18% 127
2023
Q1 		$854K Sell
22,624
-408
-2% -$15.7K 0.18% 130
2022
Q4 		$976K Buy
+23,032
New +$949K 0.2% 108
2021
Q2 		– Sell
-101,518
Closed -$3.33M – 320
2021
Q1 		$3.33M Sell
101,518
-5,899
-5% -$222K 0.6% 59
2020
Q4 		$4.37M Sell
107,417
-3,203
-3% -$120K 0.79% 38
2020
Q3 		$4.05M Buy
110,620
+256
+0.2% +$9.26K 0.88% 35
2020
Q2 		$3.74M Buy
110,364
+84,340
+324% +$2.3M 0.89% 33
2020
Q1 		$551K Sell
26,024
-2,914
-10% -$65K 0.13% 129
2019
Q4 		$646K Buy
+28,938
New +$632K 0.1% 165

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Navellier & Associates's GMAB Position: Q4 2023 in Review

Navellier & Associates sold out of Genmab (GMAB) in Q4 2023, closing a stake of 25,600 shares — an estimated $903K sold.

Navellier & Associates first reported a position in GMAB in Q4 2019 and held it in 10 quarters. The position peaked at $4.37M in Q4 2020. 225 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • Navellier & Associates reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • Navellier & Associates sold 25,600 Genmab shares in Q4 2023, an estimated $903K.
  • Navellier & Associates first reported a position in Genmab in Q4 2019 and held it in 10 quarters.
  • Navellier & Associates's Genmab position peaked at $4.37M in Q4 2020.
  • 225 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on Navellier & Associates's 13F filing for Q4 2023, filed 8 Feb 2024.